International Biotechnology Trust (IBT)

Category Sector Equity Biotechnology


star-filledstar-filledstar-filledstar-filled
This investment trust can be held in an Investment ISA, SIPP and Investment Account
Some Investment Trusts include direct costs as part of their Ongoing charge, such as the annual management charge. For those that show Ongoing charges as 0% please review the investment literature for details on the charges that will apply. The Financial Conduct Authority will review this in 2025.

If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice.
Sell

676.00p

Buy

690.00p

arrow-up0.00p (+0.00%)

Discount/Premium

-11.07%

Estimated NAV

769.18p

Prices updated at 24 Dec 2024, 12:35 GMT
| Prices minimum 15 mins delay
|
Prices in GBX

Investment objective
The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with suitably experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.

arrow-up0.47%
LSE

Most recent dividend payment

0.156
Cash Dividend
19 Dec 2024
10 Dec 2024
20 Dec 2024
24 Jan 2025
Dividend cover-

Income only yield

No data available

Dividend per share

Income only yield data table

YearIncome only yield
2024-
2023-
2022-
2021-
2020-
2019-
2018-
2017-

Dividend per share data table

YearDividend per share
20240.3006
20230.2810
20220.2970
20210.2990
20200.2660
20190.2640
20180.4100
20170.2300


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.


Any ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
© Copyright 2024 Morningstar. All rights reserved.